Literature DB >> 26037936

Endovascular coiling vs. surgical clipping for unruptured intracranial aneurysm: A meta-analysis.

Changhu Ruan1, Hu Long, Hong Sun, Min He, Kaiyong Yang, Heng Zhang, Boyong Mao.   

Abstract

BACKGROUND: With increasing use of high-resolution imaging of brain, unruptured aneurysms are more and more frequently detected. With the advances in treatment techniques, an increasing number of aneurysms are now occluded using endovascular coiling instead of conventional surgical clipping. However, the better modality for unruptured intracranial aneurysm has been poorly understood.
OBJECTIVE: The objective of this meta-analysis was to compare the outcomes between endovascular coiling and surgical clipping among patients with unruptured intracranial aneurysms.
METHODS: PubMed, Embase, Web of Science, CENTRAL, and SIGLE were electronically searched from January 1, 1990 to March 13, 2012 with no language restriction for randomized or nonrandomized clinical controlled trials. Article screening and data extraction were conducted in duplicate. Results were statistically pooled through Review Manager 5 and StatsDirect 2.7.9.
RESULTS: Seven studies met our inclusion criteria. The pooled risk ratios (coiling vs. clipping) were 0.59 (95% CI = 0.23-1.54) for death; 0.37 (95% CI = 0.10-1.41) for bleeding; 0.78 (95% CI = 0.38-1.58) for cerebral ischemia; 0.87 (95% CI = 0.70-1.08) for occlusion of aneurysm; 0.53 (95% CI = 0.18-1.52) for independence in daily activities. The pooled rates of death, bleeding, ischemia, occlusion of aneurysm, and mRS no less than 3 were 1% (95% CI = 0-2%), 2% (95% CI = 0-5%), 8% (95% CI = 4-13%), 82% (95% CI = 64-95%), and 5% (95% CI = 1-10%) for endovascular coiling, respectively, and 1% (95% CI = 0-2%), 6% (95% CI = 3-10%), 9% (95% CI = 5-15%), 95% (95% CI = 90-98%), and 8% (95% CI = 3-14%) for surgical clipping, respectively. We failed to evaluate quality of life and cognitive outcome due to insufficient data. Both meta-regression and sensitivity analysis showed consistent results. Furthermore, Begg's test and Egger's test failed to detect publication bias.
CONCLUSION: We suggest that endovascular coiling and surgical clipping bear similar risk ratios of death, bleeding, cerebral ischemia, occlusion of aneurysm, and independence in daily activities and encourage further studies on quality of life and cognitive outcome. However, albeit the results in this meta-analysis are robust, due to great clinical heterogeneity and low quality of studies, the results in this meta-analysis should be interpreted with caution.

Entities:  

Keywords:  endovascular coiling; meta-analysis; surgical clipping; systematic review; unruptured intracranial aneurysm

Mesh:

Year:  2015        PMID: 26037936     DOI: 10.3109/02688697.2015.1023771

Source DB:  PubMed          Journal:  Br J Neurosurg        ISSN: 0268-8697            Impact factor:   1.596


  17 in total

1.  Clinical and morphological risk factors for the recurrence of anterior communicating artery aneurysms after clipping or coiling.

Authors:  Jai Ho Choi; Yong Sam Shin; Hee Jong Ki; Kwan Sung Lee; Bum Soo Kim
Journal:  Acta Neurochir (Wien)       Date:  2020-06-15       Impact factor: 2.216

Review 2.  A meta-analysis on the prevalence of anxiety and depression in patients with unruptured intracranial aneurysms: exposing critical treatment gaps.

Authors:  Katrina Hannah D Ignacio; Juan Silvestre G Pascual; Sedric John V Factor; Kathleen Joy O Khu
Journal:  Neurosurg Rev       Date:  2022-03-15       Impact factor: 3.042

3.  Microsurgical clipping and endovascular treatment of middle cerebral artery aneurysms in an interdisciplinary treatment concept: Comparison of long-term results.

Authors:  Christoph Schwartz; Hans-Christoph Aster; Rahman Al-Schameri; Erasmia Müller-Thies-Broussalis; Christoph J Griessenauer; Monika Killer-Oberpfalzer
Journal:  Interv Neuroradiol       Date:  2018-08-02       Impact factor: 1.610

4.  Interleukin Enhancer Binding Factor 2 Regulates Cell Viability and Apoptosis of Human Brain Vascular Smooth Muscle Cells.

Authors:  Liang Wei; Cheng Yang; Guangxue Wang; Keqin Li; Yanfei Zhang; Hongxin Guan; Zhiyang Sun; Chunlong Zhong
Journal:  J Mol Neurosci       Date:  2020-08-04       Impact factor: 3.444

5.  The application of the unruptured intracranial aneurysm treatment score: a retrospective, single-center study.

Authors:  Silvia Hernández-Durán; Dorothee Mielke; Veit Rohde; Vesna Malinova
Journal:  Neurosurg Rev       Date:  2018-02-01       Impact factor: 3.042

6.  Treatments for unruptured intracranial aneurysms.

Authors:  Felipe Gomes de Barros Pontes; Edina Mk da Silva; Jose Cc Baptista-Silva; Vladimir Vasconcelos
Journal:  Cochrane Database Syst Rev       Date:  2021-05-10

7.  Procedural complications in patients undergoing microsurgical treatment of unruptured intracranial aneurysms: a single-center experience with 1923 aneurysms.

Authors:  Eric S Nussbaum; Jillienne C Touchette; Michael T Madison; James K Goddard; Jeffrey P Lassig; Mark E Meyers; Collin M Torok; Jason J Carroll; Jodi Lowary; Tariq Janjua; Leslie A Nussbaum
Journal:  Acta Neurochir (Wien)       Date:  2021-09-25       Impact factor: 2.216

8.  Readmission Trends Related to Unruptured Intracranial Aneurysm Treatment.

Authors:  Tapan Mehta; Ninad Desai; Smit Patel; Shailesh Male; Adam Khan; Andrew Walker Grande; Ramachandra Prasad Tummala; Bharathi Dasan Jagadeesan
Journal:  Front Neurol       Date:  2021-05-20       Impact factor: 4.003

9.  Bazedoxifene, a selective estrogen receptor modulator, reduces cerebral aneurysm rupture in Ovariectomized rats.

Authors:  Hidetsugu Maekawa; Yoshiteru Tada; Kenji Yagi; Takeshi Miyamoto; Keiko T Kitazato; Masaaki Korai; Junichiro Satomi; Tomoki Hashimoto; Shinji Nagahiro
Journal:  J Neuroinflammation       Date:  2017-10-02       Impact factor: 8.322

10.  Cognitive Outcomes After Anterior Communicating Artery Aneurysm Repair.

Authors:  Farshad Nassiri; Adriana M Workewych; Jetan H Badhiwala; Michael D Cusimano
Journal:  Can J Neurol Sci       Date:  2018-05-09       Impact factor: 2.104

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.